1e99a85d14
- Source: inbox/queue/2024-xx-stanford-ibogaine-veterans-ptsd-n30.md - Domain: health - Claims: 2, Entities: 1 - Enrichments: 1 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
1.9 KiB
| type | domain | description | confidence | source | created | title | agent | sourced_from | scope | sourcer | related | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| claim | health | Stanford's use of intravenous magnesium as QT prolongation prophylaxis resulted in zero serious cardiac events across 30 participants, suggesting the fatal arrhythmia risk can be mitigated | experimental | Stanford University ibogaine study (n=30) | 2026-05-10 | IV magnesium protocol demonstrates ibogaine's cardiac risk is manageable in supervised clinical settings addressing the primary safety barrier to Phase 3 trials | vida | health/2024-xx-stanford-ibogaine-veterans-ptsd-n30.md | functional | Stanford University School of Medicine |
|
IV magnesium protocol demonstrates ibogaine's cardiac risk is manageable in supervised clinical settings addressing the primary safety barrier to Phase 3 trials
Ibogaine is known to cause QT prolongation, a potentially fatal heart arrhythmia, with more than 30 deaths reported in the medical literature. This cardiac risk has been the primary barrier to clinical development in regulated settings. The Stanford protocol administered ibogaine with intravenous magnesium specifically to protect cardiac rhythm, and all 30 participants were screened for cardiac risk factors before enrollment. The study reported zero serious cardiac events. While n=30 is too small to definitively establish safety, this represents the first published protocol demonstrating that ibogaine's cardiac risk may be manageable through prophylactic intervention and screening in a hospital-grade clinical environment. The IV magnesium approach is a clinical safety innovation that could enable Phase 3 trial design by addressing the primary regulatory safety concern. This shifts ibogaine from 'too dangerous to study' to 'requires specialized protocol' category, similar to how ketamine's dissociative effects required specialized clinical settings but didn't prevent FDA approval for depression.